RE:Material News Well two items checked off my list beliw with Turkish Health
Authority and Health Canada approvals.
We are getting very close to first patient dosed and then we are off to the races.
The algorithms continue to hold us back but in all fairness we need buyers to step in.
There could be some positive twists and turns that happen after the first 100 patients are dosed. Investors need to keep in mind a few facts. Arch has amble supply of their drug produced, more then what they required for this phase 2 trial. Arch demonstarted last summer that humans could tolerate increased dosage thus results from new AKI study using increased dosage could and should produce even better results for the new AKI phase 2 trial thst is commencing.
There are currently no treatments for AKI other then dialysis or kidney transplants. I personally believe the results will be better then initially anticipated especially coupled with increased dosage, the fact there is no treatment for AKI could open the door to emergency usuage authorization hence the large supply of the drug that Arch is sitting on. It would not surprise me that they apply for Emergency Authorization Usuage after say 100 patients dosed.
My fingers are crossed.
Respectfully
Viking2233 wrote: This stock will continue to struggle until we receive material news. Application news will not and has not had any impact positively or negatively.
We need the following:
1. Turkish Approval
2. Health Canada Approval
3. Number of hospitals participating in each
4. First dosing
5. Results from Data
6. Oh how about the 3rd party independent review of previous phase 2, which has taken years not too mention already 6 months past due
These items above will impact share price positively.